Pfizer Sees Celebrex Script Growth After Bextra Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Script data indicates patients are switching from Bextra to Celebrex, Pfizer says. In the last three weeks, Celebrex has led the NSAID market in new prescription growth.
You may also be interested in...
Celebrex On The “Rebound,” Pfizer Says
Celebrex has nearly regained the market share it lost during the COX-2 inhibitor safety controversy, Pfizer said Jan. 19
Celebrex On The “Rebound,” Pfizer Says
Celebrex has nearly regained the market share it lost during the COX-2 inhibitor safety controversy, Pfizer said Jan. 19
Silver Lining For Pfizer? Celebrex Well-Positioned In NSAID Class
The boxed warning for Pfizer's Celebrex will differ only slightly from labeling for other prescription NSAIDs, FDA says. All products will bear new language addressing increased cardiovascular and gastrointestinal risks. The agency appears open to renewed direct-to-consumer advertising for Celebrex.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: